Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 3/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15866749 | 0.93 | PARP14 (0.40) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL14898026 | 0.92 | PARP14 (0.43) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL14898023 | 0.90 | PARP14 (0.40) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL1668933 | 0.89 | PARP14 (0.44) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL14898221 | 0.88 | PARP14 (0.42) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL14898164 | 0.88 | PARP14 (0.43) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL14898212 | 0.87 | PARP14 (0.41) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL15866721 | 0.87 | PARP14 (0.38) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL1668831 | 0.86 | PARP14 (0.40) | PARP14PARP10ALDH1A1KDM4ELMNA | |
| SCHEMBL15866724 | 0.86 | ACHE (0.49) | KDM4ETPSAB1CNR2ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2013058824-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | PARP14 1916/4885PARP10 1991/4885ALDH1A1 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.